OAN Staff Lillian Mann
6:19 PM – Thursday, August 13, 2026
In a Thursday statement, the White House highlighted that prescription drug prices in the United States have dropped to a record 60-year low.
President Donald Trump has long pledged to lower prescription drug costs, and the White House credited these recent price cuts to TrumpRx — a service that delivers select medications directly to patients’ homes. Highlighting the high cost of GLP-1 weight-loss medications, which Trump informally dubbed the “fat drug,” officials pointed to the platform’s entry-level doses starting at $150.
On Thursday, the White House declared that prescription drug prices are now plummeting thanks to President Trump’s ongoing efforts to slash prices.
“Prescription drug prices PLUMMETING,” the post read. “Thanks to President Trump’s promise to SLASH prescription drug costs and TrumpRx, drug prices just saw their sharpest drop in more than 60 YEARS. MORE WINNING FOR AMERICA!”
According to Bureau of Labor Statistics data released Wednesday, prescription drug prices dropped by at least 3.1%, marking their steepest annual decline since March 1963. Even as overall medical service costs continued to climb, prices for medicinal drugs fell 2.7% over the 12 months ending in July — the largest annual drop ever recorded.
While U.S. consumers continue to face persistent inflation, prescription drug prices have defied the broader trend, falling at a record pace.
“No president in modern history has been able to drastically reduce prescription drug prices across the board except for President Trump,” White House spokesman Kush Desai said in an email. “This is a direct result of the President’s willingness to push the envelope with bold policies that actually put Americans and America First.”
“In a matter of months, we got these discounts up and running so that they were meaningful for American patients,” a White House spokesperson also remarked.
The Bureau of Labor Statistics measures the total revenue a pharmacy earns per prescription — combining patient copays with insurance and Medicare Part D payouts — rather than tracking raw drug manufacturer list prices.
Because of this, a drop in the index reflects overall lower consumer and program spending, driven by higher insurance discounts, government price caps and patient shifts toward cheaper medications or direct-pay services like TrumpRx.
Stay informed! Receive breaking news alerts directly to your inbox for free. Subscribe here. https://www.oann.com/alerts
What do YOU think? Click here to jump to the comments!
Sponsored Content Below
Be the first to comment